Lara Meisner - 12 Dec 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
General Counsel and Secretary
Signature
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Issuer symbol
VRDN
Transactions as of
12 Dec 2022
Transactions value $
-$82,701
Form type
4
Date filed
14 Dec 2022, 19:56
Previous filing
16 Nov 2022
Next filing
19 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $13.8K +600 $23.03 600 12 Dec 2022 Direct
transaction VRDN Common Stock Sale -$16.8K -600 -100% $28.05 0 12 Dec 2022 Direct F1
transaction VRDN Common Stock Options Exercise $361K +15.7K $23.03 15.7K 14 Dec 2022 Direct
transaction VRDN Common Stock Sale -$440K -15.7K -100% $28.12 0 14 Dec 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -600 -0.75% $0.00 78.9K 12 Dec 2022 Common Stock 600 $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -15.7K -19.84% $0.00 63.2K 14 Dec 2022 Common Stock 15.7K $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.02 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.33. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.